Viracta Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Forward Ventures V, LP, along with its affiliates, has filed a Schedule 13G indicating a passive beneficial ownership of 4.3% of Viracta Therapeutics, Inc.'s common stock as of December 31, 2024.